Management of Neutropenia in Cancer Patients

Neutropenia, a reduction in circulating neutrophils, represents a common and potentially life-threatening complication of myelosuppressive chemotherapy. Management hinges on prompt risk assessment, targeted prophylaxis and judicious use of antimicrobial and haematopoietic interventions. Initial strategies focus on stratifying patients into low- and high-risk categories according to anticipated duration of neutropenia, comorbidities and clinical presentation. High-risk individuals often receive prophylactic granulocyte colony-stimulating factors (G-CSFs) to accelerate marrow recovery and reduce incidence of febrile neutropenia. Empirical broad-spectrum antibiotics are deployed at first sign of fever in neutropenic patients, with agents selected to cover Pseudomonas aeruginosa and other likely pathogens. Antimicrobial stewardship principles guide early de-escalation once cultures and clinical stability permit, reducing collateral damage and resistance. Recent advances include oral antibiotic switch protocols for low-risk febrile episodes, integration of biosimilar G-CSFs to improve access and cost-effectiveness, and adaptive outpatient models that balance safety with reduced hospital stay. Supportive care also encompasses vigilant monitoring of blood counts, dose modifications of chemotherapy based on neutropenic events and incorporation of new biomarkers to predict risk. Global efforts aim to harmonise guidelines, optimise resource allocation and foster patient-centred pathways that maintain chemotherapy intensity while minimising infection-related morbidity and economic burden.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Neutropenia in Cancer Patients publication trend

The graph below shows the total number of articles in management of neutropenia in cancer patients across all publications each year (not limited to Nature Index journals).

Technical terms

Neutropenia: A decrease in absolute neutrophil count, typically below 1.5×10⁹ cells/L, increasing infection risk.

Febrile neutropenia: The occurrence of fever (≥38.3 °C) in a neutropenic patient, signalling possible severe infection.

Granulocyte colony-stimulating factor (G-CSF): A haematopoietic growth factor administered to accelerate neutrophil recovery after chemotherapy.

Empirical therapy: Initial antimicrobial treatment given before specific pathogen identification, guided by likely organisms and patient risk.

Risk stratification: Assessment of patient-specific factors to categorise neutropenic episodes as low or high risk, directing intensity of intervention.

Antimicrobial de-escalation: The process of narrowing or discontinuing broad-spectrum antibiotics based on clinical improvement and microbiology results.

References

1. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Clinical Microbiology and Infection (2023).
2. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?. The Oncologist (2022).
3. Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplantation (2020).